Karyopharm Therapeutics Inc.KPTINASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.70% | -9.50% | -9.39% | -11.35% | +13.57% |
| Gross Profit Growth | +6.80% | -9.24% | -7.76% | -10.56% | +11.87% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | -178.74% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -256.57% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -292.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.27% | +9.67% | +10.04% | +6.84% | +4.02% |
| Weighted Average Shares Diluted Growth | +9.27% | +9.67% | +10.04% | -16.27% | +4.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -16.20% | +14.11% | +13.39% | -13.33% | +0.31% |
| Inventory Growth | +50.47% | +55.73% | +72.23% | +43.61% | -15.11% |
| Asset Growth | -29.81% | -31.62% | -37.54% | -50.99% | -49.21% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +9.40% | +9.89% | +5.82% | -2.56% | +1.11% |
| R&D Expense Growth | +1.63% | -15.27% | -2.04% | -14.35% | -15.47% |
| SG&A Expenses Growth | -10.30% | -11.40% | -7.44% | -8.35% | -3.71% |